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Abstract 
Aim: Oxidative stress is associated with progression of chronic liver disease (CLD). 
This association is best established in chronic hepatitis C. However, the anti-oxidative 
state is not well characterized. The objective of the present study was to investigate the 
balance of oxidative and anti-oxidative stress in CLD patients. 
Methods: We recruited a study population of 208 patients, including healthy volunteers 
(HV; n = 15), patients with hepatitis B virus (HBV)-related CLD without or with 
hepatocellular carcinoma (HBV-nonHCC, n = 25, and HBV-HCC, n = 50, respectively), 
and patients with hepatitis C virus (HCV)-related CLD without or with HCC 
(HCV-nonHCC, n = 49, and HCV-HCC, n = 69, respectively). Serum levels of reactive 
oxygen metabolites (ROM) and anti-oxidative markers (OXY-adsorbent test; OXY) 
were determined, and the balance of these values was used as the oxidative index. 
Correlations among ROM, OXY, oxidative index, and clinical characteristics were 
investigated. 
Results: Patients with CLD exhibited elevated ROM and oxidative index compared to 
HV. Among patients with CLD, HCV-positive status correlated with increased ROM. In 
CLD, HCV-HCC patients exhibited the highest ROM levels. Among HCV-related 
CLD patients, lower OXY correlated with HCC-positive status, but was recovered 
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by eradication of HCC. In HCV-HCC, lower OXY correlated with high PT-INR. 
Conclusions: HCV-positive CLD patients displayed higher oxidative stress and 
HCV-HCC patients displayed lower anti-oxidative state. Anti-oxidative state 
depression was associated with liver reservoir-related data in HCV-HCC and could 
be reversed with HCC eradication. 
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Introduction 
Oxidative stress is increasingly recognized as a key factor in the progression of 
chronic liver disease (CLD). CLD usually results from hepatitis B virus (HBV) 
infection, hepatitis C virus (HCV) infection, alcoholic liver disease, autoimmune 
hepatitis, primary biliary cirrhosis, and non-alcoholic steatohepatitis. Of these, chronic 
hepatitis C has been noted as a source of strong oxidative stress1, resulting in a high rate 
of hepatocarcinogenesis among patients with cirrhosis2. The liver, a metabolically 
important organ, is a major reservoir of the mitochondria that serves as the source of 
reactive oxygen species (ROS). As a result, CLD could represent a major inducer of 
oxidative stress. In addition, HCV itself induces oxidative stress on hepatocytes3, 4. 
HCV-induced oxidative stress suppresses production of hepcidin, a negative regulator of 
iron absorption, thereby resulting in iron deposition. Chronic hepatitis C patients exhibit 
iron overload in the liver, and the accumulation of iron contributes to increased DNA 
damage and elevated lipid peroxidation5, 6. In addition, chronic hepatitis C patients show 
significant alteration of the mitochondria, and various HCV proteins elicit the 
generation of mitochondrial ROS in vitro3, 7. Levels of the oxidative stress marker 
8-hydroxy-2’-deoxyguanosine (8-OHdG) are reportedly elevated in the livers of patients 
with chronic hepatitis C compared to those from patients with other CLDs2. The 
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production of 8-OHdG is particularly elevated in patients with HCV-related 
hepatocellular carcinoma (HCC)8. Together, these in vitro and in vivo findings suggest 
the association of enhanced oxidative stress with chronic hepatitis C. 
A major endogenous antioxidant produced by cells is glutathione (GSH). The liver 
is one of the primary sources of GSH. Hepatic and blood GSH levels are reduced in 
chronic hepatitis C patients, indicating that anti-oxidative status is attenuated in these 
patients5. Several in vitro experiments suggest that HCV core protein compromises the 
antioxidant system in the liver, including heme oxygenese-1 and NADH dehydrogenase 
quinone 19, 10. However, several other groups have reported that antioxidant levels are 
increased upon expression of HCV core or polyproteins11, 12. These seemingly disparate 
effects could be due to the status of p53, aging, or the presence of other sources of ROS 
(e.g., inflammation), leading to a greater level of oxidative stress that overwhelms the 
antioxidant defenses in vivo13. Thus, although increased oxidative stress in chronic 
hepatitis C patients is widely accepted, anti-oxidative conditions in these patients 
remain unresolved. 
The objective of the present study was to investigate the balance between oxidative 
stress and anti-oxidative stress in patients with chronic viral liver diseases. Serum levels 
of reactive oxygen metabolites (ROM) were determined as a marker of circulating 
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ROS14, 15. The OXY-adsorbent test was also performed to evaluate the corresponding 
anti-oxidative status16. We investigated possible correlations among ROM and OXY 
values and the clinical parameters and course of CLD in our patient population. 
 
Methods 
Subjects 
The study group comprised 5 groups. The first group consisted of 15 healthy volunteers 
(HV). The second group (HBV-nonHCC) consisted of 25 patients with HBV-related 
CLD without HCC. The third group (HBV-HCC) consisted of 50 patients with both 
HBV-related CLD and HCC. The fourth group (HCV-nonHCC) consisted of 49 patients 
with HCV-related CLD without HCC. The fifth group (HCV-HCC) consisted of 69 
patients with HCV-related CLD with HCC. Twenty HCV-nonHCC patients and 25 
HCV-HCC patients were followed for 16 months and 17 months, respectively, with 
data compared at a second time point after follow-up. HV consisted of patients with 
no systemic diseases who were admitted to the Preventive Dentistry Clinic. Members of 
this group were age-matched with overall CLD patients, since aging is one of the main 
sources of oxidative stress. Serum levels of ROM and anti-oxidative OXY-adsorbent 
test (OXY) were determined (see below), and the balance between ROM and OXY was 
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used to define the oxidative index. Correlations between ROM, OXY, oxidative index, 
and clinical characteristics were assessed for all patients. All patients were recruited at 
the Clinic of Gastroenterology and Hepatology, and all HV were recruited at the 
Preventive Dentistry Clinic, Okayama University Hospital, between August 2008 and 
December 2010. The study protocols were approved by the Ethics Committee of 
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences. After obtaining written informed consent, a detailed medical questionnaire 
was completed by doctors or dentists. 
 
Blood sample collection and preparation 
Fasting blood samples were collected from patients and healthy volunteers. Serum was 
collected at the time of admission or at the outpatient clinic, meaning that no 
intervention had been performed before specimen collection. If not assayed immediately, 
serum aliquots were stored at -80°C until subsequent analysis. The obtained samples 
were used to determine biochemical data, including serum levels of ROM and OXY. 
 
Measurement of ROM serum levels 
Measurement of ROM serum levels was performed using a spectrophotometer (Diacron 
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International, Grosseto, Italy), as reported previously14. The measurement unit used was 
the Carratelli unit (CARR U), where 1 CARR U corresponds to 0.08 mg/dL of hydrogen 
peroxide. 
 
Measurement of total serum anti-oxidant capacity 
In order to determine total serum anti-oxidant capacity, OXY was performed using a 
spectrophotometer (Diacron International)16. This test evaluates the capacity of serum to 
oppose the massive oxidative action of a hypochlorous acid (HClO) solution. Total 
anti-oxidant capacity was expressed in terms of HClO (μmol) consumed by 1 mL of 
sample (μmol HClO/mL). 
 
Calculation of oxidative-anti-oxidative balance 
The balance between oxidative stress and anti-oxidative stress was calculated as an 
oxidative index. To incorporate parameters with differing measurement units, the 
standardized values of ROM and OXY were assessed using the formula of Vassale et 
al.17: sv-var = (v-var - m-var) / ds-var. In this formula, sv-var represents the standard 
value of a certain parameter, v-var corresponds to the original value, and m-var and 
ds-var represent the mean and standard deviation of the parameter, respectively. The 
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oxidative index was calculated by subtracting the OXY standardized variable from the 
ROM standardized variable. The HV group was used as the reference population for 
calculating the means and standard deviations of ROM and OXY. 
 
Liver biopsy interpretation and immunohistochemistry for oxidative stress-related 
marker 4-hydroxy-2-nonenal (4-HNE) 
Liver histology was available for 44 patients in the HCV-related CLD group. Liver 
tissues were fixed with 10% formalin and embedded in paraffin. Cross-sections 
(5-μm thick) were cut and stained using hematoxylin and eosin (HE) and Azan. All 
liver specimens were assessed by two hepatologists (T.Y. and A.T.) who were 
blinded to study group allocations. The METAVIR scoring system was used to 
analyze the stage of liver fibrosis in patients. Two patients had no fibrosis, 19 
patients had stage 1 fibrosis, 5 patients had stage 2 fibrosis, 7 patients had stage 3 
fibrosis, and 11 patients had stage 4 fibrosis. 
For immunohistochemical staining of 4-HNE, sections were incubated with 
primary antibody against 4-HNE (1:100 dilution; Nikken Seil, Tokyo, Japan) at 
4˚C overnight. Following rinsing with phosphate-buffered saline, sections were 
incubated with biotinylated secondary antibody (LSAB+System-HRP; DAKO, 
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Carpinteria, CA) for 30 min and the avidin/biotin system for 30 min and visualized 
using 3,3’-diaminobenzidine (DAB) solution (0.05% DAB and 0.003% hydrogen 
peroxide in 0.1M PB). After stopping the reaction with de-ionized water, sections 
were counterstained with hematoxylin. Positive staining was characterized by 
brownish staining in the cytoplasm of hepatocytes. 
 
Statistical analysis 
Statistical analysis was conducted using the JMP version 9.0.0 software (SAS Institute, 
Carry, NC). Continuous variables were expressed as median values (interquartile range), 
and the Mann-Whitney U-test or chi-squared test was used to compare parameters 
between HV and CLD groups. The multifactorial Steel-Dwass analysis was used to 
compare parameters among the HBV-nonHCC, HBV-HCC, HCV-nonHCC, and 
HCV-HCC groups. Distributions of oxidative stress-related markers in patient groups 
were compared using the chi-squared test. Follow-up data were compared using the 
Wilcoxon signed-rank test. Statistical significance was set at P < 0.05. Univariate 
analysis was performed in CLD patients to identify factors potentially correlated with 
oxidative stress-related markers. Age, which is widely accepted as an oxidative stress 
factor, and any variables yielding P < 0.05 in the univariate analysis were analyzed 
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further by multivariate analysis to identify independent factors correlated with oxidative 
stress-related markers. 
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Results 
Baseline characteristics of the groups 
The clinical characteristics of the study groups are shown in Table 1. No significant 
differences between HV and CLD groups were seen with regard to age or body mass 
index (BMI), although the sex distribution and data for multiple clinical parameters did 
differ significantly between groups (Table 1A). The clinical characteristics of CLD 
groups are shown in Table 1B. For further analysis, CLD patients were sorted into 
subgroups (HBV-nonHCC, HBV-HCC, HCV-nonHCC, and HCV-HCC) depending on 
viral and HCC status. HBV-nonHCC group patients were younger than the others, 
but no age differences were apparent between other groups. Sex distribution and 
BMI were comparable between groups. In HCC-positive groups (i.e., HBV-HCC 
and HCV-HCC), platelet counts were lower and PT-INR was longer than in 
nonHCC groups, suggesting splenomegaly and liver reservoir dysfunction in these 
patients. Among the 49 HCV-nonHCC patients, four patients with lower albumin 
levels developed HCC during follow-up after examination of oxidative 
stress-related markers (median, 39 months; Table 1C). 
The follow-up study of HCV-nonHCC (median interval, 16 months) and 
HCV-HCC (median interval, 17 months) revealed no change in clinical data over these 
14 
 
 
 
periods (Table 1D). The procedures performed most often for HCC treatments 
were surgery or radiofrequency ablation therapy (RFA) (15/25). Transarterial 
chemoembolization (TACE) was performed with epirubicin up to 20 mg/body 
mixed with lipiodol and arterial embolization with gelatin particles (7/25). 
Chemotherapies were oral sorafenib administration or 5-fluorouracyl (5FU) plus 
cisplatin infusion chemotherapy (3/25). Treatment response was assessed with the 
Response Evaluation Criteria in Solid Tumors (RECIST). Fifty-two percent (13/25) of 
HCV-HCC patients showed complete response (CR) at the second time point. Only 4% 
(1/25) of patients showed partial response (PR) and 24% (6/25) showed stable disease 
(SD). Twenty percent (5/25) showed progressive disease (PD), including lung 
metastasis. 
 
Correlation between intrahepatic and serum oxidative stress-related markers 
To define the relationship between serum oxidative stress markers and 
intrahepatic oxidative stress-related conditions, we evaluated the correlation 
between expression of the intrahepatic oxidative stress marker 4-HNE and serum 
ROM levels (Fig. 1). Patients with positive intrahepatic 4-HNE expression showed 
higher serum ROM levels. 
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Oxidative stress-related markers in CLD patients 
Both the oxidative stress marker ROM and calculated oxidative index were significantly 
higher in patients with CLD than in the HV group; these two groups did not differ 
significantly in the anti-oxidative stress marker OXY (Fig. 2A). Among CLD patients, 
ROM differed significantly for HCV-nonHCC and HCV-HCC vs. HBV-HCC, OXY 
differed significantly for HCV-HCC vs. HBV-HCC and HCV-nonHCC, oxidative index 
differed significantly for HCV-HCC vs. all others (Fig. 2B). 
 
Oxidative stress-related markers and clinical characteristics 
To define the impact of oxidative stress-related markers in CLD, correlations between 
clinical characteristics and oxidative stress-related markers were analyzed (Table 2A). 
Older (≥62 years old), HCV-positive and lower serum albumin patients showed higher 
ROM values in univariate analysis; HCV-positive status was the only factor that 
exhibited a correlation in multivariate analysis. Low OXY value, indicating 
diminished anti-oxidative function, correlated (in univariate analysis) with several 
factors, including HCC-positive status, reduced ferritin, reduced platelet counts, 
higher PT-INR and lower albumin. In multivariate analysis, lower albumin status 
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was the only factor that correlated with low OXY value. The results of univariate 
analysis suggested that reduced OXY values were indicative of impaired liver 
function. The high oxidative index correlated with lower serum albumin in 
multivariate analysis. 
To reveal the correlation between progression of CLD and reduction of OXY 
value, relationships between clinical parameters indicative of liver reservoir and 
OXY were determined (Fig. 3). Patients with advanced CLD as histologically 
proven F4 tended to show lower OXY, although no significant difference was 
apparent. 
 
Oxidative stress-related markers in HCV-positive CLD patients 
Since HCV positivity correlated with oxidative stress-related markers, we next analyzed 
stratified data in patients with HCV-related CLD (Table 2B). Among patients with 
HCV, higher ROM correlated with higher HCV-RNA titer and lower PT-INR. 
Although multivariate analysis did not reveal any significant correlation, 
HCV-RNA titer showed the best correlation (P = 0.080). HCC-positive status 
correlated significantly with OXY in multivariate analysis. Several liver 
reservoir-related parameters, including platelet counts, PT-INR and albumin levels, 
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demonstrated significant correlations with OXY in univariate analysis. 
 
Oxidative stress-related markers in HCV-positive HCC patients 
Since HCC-positive status correlated with OXY in patients with HCV-related CLD, we 
next analyzed data in HCV-positive HCC patients. In HCC patients, ROM did not 
correlate with tumor stage, tumor marker levels, or liver function parameters. Higher 
HCV-RNA titer was the only factor showing a positive correlation with higher 
ROM, even in univariate analysis. Conversely, OXY correlated with PT-INR levels in 
multivariate analysis. Anti-oxidative status thus correlated with liver function 
parameters even in HCV-positive HCC patients; markers of oxidative stress were 
elevated at all stages of HCV-positive HCC. 
 
Follow-up of oxidative stress markers in HCV-positive CLD patients 
Follow-up data after about one and a half years (median: 16 months for HCV-nonHCC; 
17 months for HCV-HCC) were collected from HCV-positive CLD patients (Fig. 4A). 
In HCV-nonHCC, the three oxidative stress-related markers showed no change during 
follow up. Three patients received pegylated interferon and ribavirin treatment 
that resulted in sustained viral eradication. Oxidative stress-related markers 
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showed no change in these patients, while two patients showed OXY increase (Fig. 
4B). In HCV-HCC, OXY was increased in the CR group (Fig. 4C,D). 
 
Follow-up of HCV-nonHCC patients 
All HCV-nonHCC group patients were followed for a median of 39 months at our 
hospital, with four developing HCC. To define whether oxidative stress affects 
hepatocarcinogenesis, oxidative stress markers were compared between patients 
who did and did not develop HCC later (Fig. 5). Although only 4 patients 
developed HCC later and no significant differences were identified, median OXY 
tended to be lower than that in patients who did not develop HCC later. 
 
Discussion 
In the present study, serum ROM reflected the level of intrahepatic oxidative 
stress and was higher in patients with CLD, particularly in HCV-positive patients 
with a high titer of HCV-RNA. In contrast, anti-oxidative status OXY was attenuated 
in HCV-positive HCC patients. The follow-up data revealed that OXY attenuation in 
HCV-HCC could be reversed by eradication of HCC. 
ROM is considered to be a reliable indicator of circulating ROS14, 15. ROS 
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reportedly induce progression of HCC18, inducing the synthesis and activation of a large 
series of cytokines and growth factors, which in turn lead to malignant transformation19. 
The present results suggest that oxidative stress is increased in HCV-positive patients, 
particularly those with a high titer of HCV-RNA. 
This study also showed that serum levels of ROM were elevated in CLD patients 
compared to control subjects. These observations indicate that CLD, including that 
resulting from HBV-positive status, induces increases in systemic ROS. This result is 
consistent with a previous report demonstrating that HBV X protein induced ROS 
production in vitro20, and with a previous report of increased serum levels of 
malondialdehyde (an indicator of lipid peroxidation) in HBV-positive patients21. 
In previous work, we demonstrated that HCC patients with periodontitis had 
increased levels of ROM, and that patients with advanced HCC had severe 
periodontitis22. In contrast, the present results revealed no correlation between ROM 
and tumor factors or any liver reservoir-related parameter in HCV-positive HCC 
patients. Presumably, additional factors or conditions (such as periodontitis) that induce 
ROS contribute to the distinction between early and advanced stages of HCC. 
The main pathology of HCV-related disease is considered to reflect the immune 
reaction to virus-infected hepatocytes. The lack of strong Th1-type helper T cell 
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response and cytotoxic T cell response against HCV lead to chronic infection by this 
virus. Strong Th1-type helper T cell response and cytotoxic T cell response correlate 
with spontaneous recovery and interferon-induced sustained virological response23. 
Recent studies have focused on the direct effects of HCV on hepatocytes. Several 
studies have uncovered the distribution of viral proteins and revealed viral association 
with subcellular organelles, such as mitochondria, endoplasmic reticula (ER), and lipid 
droplets to facilitate replication and assembly of viral particles24. HCV core protein is 
closely associated with the mitochondria and causes increases in ROS, reactive nitrogen 
species production and lipid peroxidation25. HCV NS5A protein is involved in ER stress 
and disturbance of intracellular Ca2+ homeostasis, which leads to increased 
mitochondrial ROS production26. The non-structural proteins encoded by HCV induce 
strong mitochondrial injury, while production of the HCV full genome-length protein 
induces moderate mitochondrial injury, representing the cross-action of HCV core and 
non-structural proteins27. HCV-induced oxidative stress is thus implicated in the disease 
progression of chronic hepatitis. However, oxidative stress is physiologically important 
to protect cells from viral infection. ROS can rapidly inhibit HCV-RNA replication in 
HCV replicon-harboring cells28, and antioxidants such as vitamin E, vitamin C, and 
coenzyme Q4 reverse oxidative effects and thereby permit HCV replication29. Clinical 
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studies of antioxidant therapies for chronic hepatitis C have yielded disappointing 
results, with no effects seen on ALT, viral load, or interferon sensitivity30, 31. Instead, 
providing a balance between oxidative stress and anti-oxidative stress might be 
important in assessing the potential use of antioxidants to treat CLD. 
Total serum antioxidant levels, as assessed by OXY, were diminished specifically in 
patients with HCV-related HCC. This observation was consistent with the high ROM 
values in these patients. However, markers for liver reservoir function (e.g., albumin, 
PT-INR) or liver fibrosis (e.g., platelet counts) correlated with OXY in univariate 
analysis, and albumin level was the only factor in multivariate analysis. In 
HCV-positive patients, HCC-positive status (P = 0.048) correlated with lower OXY 
in multivariate analysis. In HCV-positive HCC patients, higher PT-INR level was the 
only factor that correlated with lower antioxidant capacity. Liver reservoir function 
might be involved in anti-oxidative state. In in vitro analysis, an HCV subgenomic 
replicon has been shown to induce the production of multiple antioxidant enzymes. 
Despite this effect, the overall redox environment was oxidative, since the oxidative 
stress induction was strong enough to overcome the antioxidant power27. Adequate 
oxidative-anti-oxidative balance is expected to be important for improved outcomes of 
chronic hepatitis C. 
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Stage progression of HCC did not correlate with ROM or OXY. Since our 
HCV-HCC subjects included mainly patients with early stage HCC (36% stage I, 
28% stage II; Table 1B) and because HCV-HCC follow-up subjects included 48% 
of stage I and 28% of stage II patients (Table 1D), these results must be regarded 
as an early HCC phenomenon. 
Indeed, our results revealed that oxidative index was independently elevated in 
HCV-positive and HCC-positive CLD patients. The balance of oxidative stress is more 
oxidative in HCV-positive HCC patients, and antioxidant therapy might be effective for 
such patients.  
The follow-up study revealed that OXY reduction was recovered after complete 
remission (CR) of HCC. Since our follow-up HCV-HCC group comprised patients 
with early stage HCC (stage I, 48%; Stage II, 28%) following high CR frequency, 
these changes are characteristic of early stage HCC with good treatment response. As 
the reduced anti-oxidative condition could be recovered by eradication of HCC, 
the anti-oxidative condition could be a result of HCV-positive HCC. However, 
relatively lower serum OXY was identified in HCV-nonHCC patients who 
developed HCC, suggesting a possible mechanism for the anti-oxidative state in 
hepatocarcinogenesis. To clarify whether oxidative stress is a cause or result of 
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HCC, more patients with longer follow-up need to be accumulated. 
In conclusion, oxidative stress was higher in HCV-positive patients compared to 
healthy controls and HBV-positive patients with HCC. Anti-oxidative stress 
(assessed as OXY) was lowest in HCV-positive HCC patients and could be recovered 
by tumor eradication. This distinction was most apparent in patients with higher 
PT-INR, suggesting that liver reservoir function might be important for maintaining 
anti-oxidative function. The oxidative-anti-oxidative balance was most biased towards 
the oxidative state in HCV-positive HCC patients. 
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Figure Legends 
Figure 1: Immunohistochemical staining of oxidative stress marker 4-HNE in 
liver biopsy specimens. (A) Negative staining. (B) Positive staining in the 
hepatocyte cytoplasm is shown by arrows. (C) The positive correlation between 
intrahepatic oxidative stress and serum oxidative stress state. 
  
Figure 2: The distribution of ROM, OXY, and oxidative index in patient groups. (A) 
Comparison between HV and CLD: The ROM and oxidative index were higher in 
CLD patients. (B) Comparison among HBV-nonHCC, HBV-HCC, HCV-nonHCC, and 
HCV-HCC: Among the CLD groups, the ROM value was significantly higher (P < 
0.05) in HCV-nonHCC and HCV-HCC compared to HBV-HCC. OXY was 
significantly lower (P < 0.05) in HCV-HCC compared to that in HBV-HCC and 
HCV-nonHCC. Oxidative index was significantly higher (P < 0.05) in HCV-HCC 
than in other CLD groups. 
 HV, healthy volunteers; CLD, chronic liver disease patients; HBV-nonHCC, hepatitis B 
virus (HBV)-related CLD without hepatocellular carcinoma (HCC); HBV-HCC, 
HBV-related CLD with HCC; HCV-nonHCC, HCV-related CLD without HCC; 
HCV-HCC, HCV-related CLD with HCC. 
32 
 
 
 
Figure 3: The relationship between OXY and clinical characteristics. (A) Positive 
correlation between OXY and both platelet count and albumin level. A negative 
correlation existed between OXY and PT-INR. (B) Serum OXY levels in 
histologically confirmed chronic hepatitis and liver cirrhosis. Although not 
significant, OXY was relatively decreased in histologically confirmed liver 
cirrhosis. 
 F, METAVIR fibrosis score. 
 
 Figure 4: Oxidative stress-related marker changes after about 1.5 years. (A) The 
follow-up data change in HCV-non HCC. No change was seen in this period (median 
interval, 16 months). (B) Follow-up data changes in the three HCV-nonHCC 
patients who eradicated HCV with pegylated interferon + ribavirin therapy in 
this period. Two of these patients tended to show increased OXY, although not 
statistically significant. (C) HCV-HCC with a treatment response of CR. OXY 
level increased after follow-up period (median, 17 months interval). (D) 
HCV-HCC with treatment response PD+SD+PR. No statistical differences were 
observed. 
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Figure 5. Oxidative stress-related markers in HCV-nonHCC group patients who 
developed HCC (n = 4) and in those who did not develop HCC (n = 45) during 39 
months of follow-up. Although not significant, median OXY of patients who 
developed HCC was relatively lower than that in patients who did not later 
develop HCC. 
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Tables 
Table 1A Patient characteristics (healthy control vs chronic viral liver disease) 
 
  HV (N=15) CLD (N=193) p 
Age 65 (55-71) 62 (56-69) 0.335 
Male SEX (%) 5 (33) 126 (63) 0.021 
BMI 22 (19-23) 22 (20.5-24.5) 0.930 
Platelet(x104/mL) 22 (21-26) 13 (8-18) <0.001 
PT-INR 0.89 (0.88-0.92) 0.98 (0.95-1.04) <0.001 
Total bilirubin (mg/dL) 0.5 (0.4-0.8) 0.8 (0.6-1.1) 0.001 
Albumin (g/dL) 4.2 (4.0-4.5) 4.1 (3.4-4.3) 0.088 
ALT (IU/L) 13 (11-19) 33 (22-49) <0.001 
Creatinine (mg/dL) 0.6 (0.6-0.9) 0.7 (0.6-0.8) 0.826 
Ferritin (ng/mL) 109 (85-205) 115 (39-240) 0.649  
 HV; healthy volunteer, CLD; chronic liver disease patients, BMI; body mass index,    
PT; prothrombin time, TBil; total bilirubin, ALT; alanine aminotransferase 
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Table 1B Patient characteristics and oxidative stress markers (Chronic viral liver diseases) 
     
  
HBV-nonHCC  
(N=25) 
HBV-HCC  
(N=50) 
HCV-nonHCC  
(N=49) 
HCV-HCC  
(N=69) 
Age 39 (35-60)* 61 (55-68) 62 (59-66) 67 (59-73) 
Male SEX (%) 12 (48) 37 (74) 24 (44) 53 (76) 
BMI 21 (19-23) 22 (20-24) 22 (20-24) 22 (20-24) 
Platelet(x104/mm3) 19 (16-24) 13 (7-17)* 17 (12-22) 9 (6-12)* 
PT-INR 0.94 (0.88-1.00) 1.00 (0.96-1.09)** 0.96 (0.94-1.00) 1.02 (0.96-1.08)** 
Total bilirubin (mg/dL) 0.89 (0.65-1.05) 0.93 (0.68-1.19) 0.78 (0.55-1.01) 0.93 (0.62-1.23) 
Albumin (g/dL) 4.6 (4.3-4.8)* 4.1 (3.6-4.4) 4.2 (3.8-4.3) 3.4 (3.0-3.9)* 
ALT (IU/L) 24 (12-43) 25 (19-38)† 38 (22-65) 37 (27-49) 
Ferritin (ng/mL) 202.6 (160.1-575.5) 88.4  (38.7-194.2) 177.5 (73.1-327.4) 101.5 (27.0-197.4) 
HCV-RNA (LogIU/mL) - - 6.2 (5.2-7.0) 5.9 (4.4-6.5) 
AFP (ng/mL) 2.4 (1.9-3.5) 22.2 (3.6-188)** 5.3 (2.4-8.6) 18.0 (7.8-85.3)** 
DCP (mAU/mL) 18 (14-23) 32 (20-407)** 21 (17-28) 76 (24-251)** 
HCC stage 
I/II/III/IV 
- 20/14/7/9 - 25/19/16/9 
* p<0.05 vs all 
    
** p<0.05 vs HBV-nonHCC, HCV-nonHCC 
   
† p<0.05 vs HCV-HCC 
   
AFP; α-fetoprotein, DCP; des-γ-carboxy prothrombin 
HBV-non HCC; hepatitis B related CLD without hepatocellular carcinoma (HCC),  
HBV-HCC; hepatitis B related CLD with HCC,  
HCV-non HCC; hepatitis C related CLD without HCC, HCV-HCC; hepatitis C related CLD with HCC 
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Table 1C The characteristics of the HCV-nonHCC patients who developed HCC during observation 
(median 39 months) 
  
Hepatocarcinogenesis  
(N=4) 
No hepatocarcinogenesis  
(N=45) 
p 
Age 64 (57-69) 62 (58-66) 0.545 
Male SEX (%) 2 (50) 18 (40) 0.698 
Platelet(x104/mL) 12 (9-18) 18 (13-23) 0.093 
PT-INR 1.07 (1.00-1.09) 0.96 (0.93-1.00) 0.052 
Total bilirubin (mg/dL) 1.1 (0.6-1.9) 0.7 (0.5-0.9) 0.207 
Albumin (g/dL) 3.4 (3.1-3.9) 4.2 (4.1-4.3) 0.007 
ALT (IU/L) 56 (47-65) 33 (21-65) 0.158 
Creatinine (mg/dL) 0.64 (0.56-0.72) 0.66 (0.57-0.76) 0.682 
Ferritin (ng/mL) 95 (59-176) 132 (61-331) 0.436 
HCV-RNA (LogIU/mL) 6.2 (5.7-6.3) 6.2 (5.0-7.0) 0.984 
AFP (ng/mL) 6 (5-27) 3 (2-7) 0.147 
DCP (mAU/mL) 14 (13-26) 22 (18-28) 0.281 
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Table 1D Patient characteristics for follow up study (HCV positive patients) 
  
       
  
HCV-nonHCC  
(N=20) 
p 
HCV-HCC  
(N=25) 
p 
 
Time 1 Time 2 
 
Time 1 Time 2 
 
Age  60.5 (55-73) - - 68 (62-72) - (<0.001*) 
Interval (months) - 16 (15-17) - - 17 (13-18) (0.302*) 
Male SEX (%) 8 (40) - 20 (80) (<0.001*) 
Platelet(x104/mm3) 18.9 (16.4-24.0) 18.5 (16.4-22.4) 0.708 9.4 (5.7-12.6) 8.3 (7.1-11.5) 0.748 
PT-INR 0.95 (0.90-0.97) 0.93 (0.89-0.98) 0.163 1.03 (0.96-1.09) 1.00 (0.96-1.13) 0.914 
Total bilirubin (mg/dL) 0.77 (0.58-0.84) 0.72 (0.52-0.90) 0.876 0.93 (0.62-1.06) 1.02 (0.84-1.40) 0.052 
Albumin (g/dL) 4.2 (4.2-4.5) 4.2 (4.1-4.4) 0.402 3.5 (3.2-3.9) 3.5 (3.2-3.7) 0.899 
ALT (IU/L) 26 (20-39) 25 (17-32) 0.423 41 (35-57) 36 (25-61) 0.534 
AFP (ng/mL) 3 (2-4) 3 (2-5) 0.236 11 (5-24) 11 (4-41) 0.872 
DCP (mAU/mL) 21 (18-27) 19 (16-29) 0.916 32 (21-126) 30 (13-127) 0.146 
Intereferon treatment 
 
3/4 SVR 
    
HCC stage  
 I/II/III/IV    
12/7/5/1 16/4/1/4 <0.001 
HCC treatment 
RFA+Ope/TACE/Chemo     
15/7/3 
 
HCC outcome 
 CR/PR/SD/PD 
        13/1/6/5   
*: Wlcoxon analysis between HCV-non HCC and HCV-HCC 
    
RFA; radio frequency ablation therapy, TACE; transarterial chemoembolization  
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Table 2A Oxidative stress markers in patients with chronic liver diseases 
  
  
dROM, median 
(range)(CARR/U) 
Univariate 
P-value  
Multivariate 
P-value  
OXY, median 
(range)(CARR/U) 
Univariate 
P-value  
Multivariate 
P-value  
Oxidative Index, 
median (range) 
Univariate 
P-value  
Multivariate 
P-value  
Age (years) 
         
 ≥62 443 (389-498) 0.013 0.195 291 (262-331) 0.064 0.316 0.533 (-0.542-1.443) 0.002 0.388 
 <62 408 (348-482) 
  
304 (276-347) 
  
-0.269 (-1.100-0.652 
  
sex 
         
 Male 422 (366-492) 0.407 
 
296 (266-339) 0.841 
 
0.241 (-0.853-1.128) 0.909 
 
 female 436 (381-492) 
  
297 (267-347) 
  
-0.182 (-0.812-1.272) 
  
Etiology 
         
 HCV 454 (394-504) <0.001 0.001 291 (261-348) 0.234 
 
0.392 (-0.597-1.445) 0.001 0.079 
 HBV 394 (344-459) 
  
304 (281-337) 
  
-0.345 (-1.248-0.637) 
  
HCC 
         
 HCC 436 (370-488) 0.801 
 
291 (263-324) <0.001 0.355 0.380 (-0.600-1.437) 0.003 0.643 
 Non-HCC 422 (367-495) 
  
319 (278-358) 
  
-0.329 (-1.098-0.633) 
  
Ferritin (ng/mL) 
         
 ≥115 428 (375-492) 0.933 
 
306 (275-351) 0.007 0.199 0.005 (-1.112-0.935) 0.035 0.366 
 <115 433 (367-492) 
  
291 (255-318) 
  
0.547 (-0.563-1.439) 
  
Platelet(x104/mm3) 
         
 ≥13 427 (371-494) 0.935 
 
314 (281-350) <0.001 0.228 -0.316 (-1.119-0.907) 0.001 0.461 
 <13 433 (368-489) 
  
285 (253-317) 
  
0.554 (-0.458-1.432) 
  
PT-INR 
         
 ≥0.98 417 (360-482) 0.111 
 
288 (262-321) 0.018 0.284 0.224 (-0.688-1.215) 0.564 
 
 <0.98 439 (379-505) 
  
312 (276-348) 
  
-0.097 (-0.856-1.334) 
  
TBil (mg/dL) 
         
 <0.8 433 (379-500) 0.129 
 
295 (261-340) 0.295 
 
0.266 (-0.637-1.433) 0.126 
 
 ≥0.8 420 (362-482) 
  
297 (270-344) 
  
-0.034 (-1.075-0.871) 
  
Albumin (g/dL) 
         
 ≥4.1 414 (362-483) 0.026 0.141 318 (281-350) <0.001 0.010 -0.460 (-1.245-0.617) <0.001 0.014 
 <4.1 450 (385-506) 
  
285 (259-313) 
  
0.581 (-0.342-1.492) 
  
ALT (IU/L) 
         
 <33 424 (361-488) 0.271 
 
298 (276-338) 0.663 
 
-0.182 (-0.851-0.927) 0.317 
 
 ≥33 436 (376-495)     296 (263-344)     0.335 (-0.726-1.280)     
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Table 2B Oxidative stress markers in patients with HCV related liver diseases 
  
  
dROM, medium 
(range)(CARR/U) 
Univariate 
P-value  
Multivariate 
P-value  
OXY, medium 
(range)(CARR/U) 
Univariate 
P-value  
Multivariate 
P-value  
Oxidative Index, medium 
(range) 
Univariate 
P-value  
Multivariate 
P-value  
total 454 (394-504) 
  
291 (261-348) 
  
0.392 (-0.598-1.445) 
  
Age (years) 
        
 ≥64 463 (411-522) 0.217 0.353 281 (248-314) 0.002 0.149 0.982 (-1.63-1.555) <0.001 0.128 
 <64 446 (384-497) 
  
316 (269-361) 
  
-0.311 (-1.030-0.714) 
  
SEX 
         
 Male 455 (388-514) 0.761 
 
289 (259-338) 0.243 
 
0.642 (-0.535-1.441) 0.169 
 
 female 446 (407-494) 
  
301 (262-350) 
  
-0.182 (-0.798-1.508) 
  
HCC 
         
 HCC 455 (393-531) 0.271 
 
277 (247-296) <0.001 0.048 0.982 (-0.012-1.679) <0.001 0.159 
Non-HCC 446 (392-485) 
  
342 (284-371) 
  
-0.440 (-1.119-0.503) 
  
HCV-RNA (LogIU/ml) 
        
 ≥5.9 466 (415-521) 0.029 0.080  295 (264-352) 0.445 
 
0.555 (-0.417-1.538) 0.393 
 
 <5.9 432 (363-497) 
  
291 (259-340) 
  
0.335 (-0.688-1.341) 
  
Ferritin (ng/ml) 
        
 ≥115 451 (391-505) 0.435 
 
297 (270-355) 0.005 0.066 0.059 (-0.808-1.013) 0.002 0.078 
 <115 466 (397-509) 
  
279 (245-313) 
  
0.733 (-0.104-1.646) 
  
Platelet(x104/ml) 
        
 ≥12 459 (411-508) 0.525 
 
323 (286-361) <0.001 0.202 -0.352 (-0.971-1.014) <0.001 0.185 
 <12 450 (383-504) 
  
276 (245-298) 
  
0.702 (-0.080-1.570) 
  
PT-INR 
         
 ≥0.98 435 (373-495) 0.039 0.298 276 (249-314) 0.005 0.062 0.506 (-0.382-1.551) 0.501 
 
 <0.98 465 (421-521) 
  
309 (278-352) 
  
0.420 (-0.635-1.452) 
  
TBil (mg/dl) 
        
 <0.8 461 (412-528) 0.168 
 
293 (256-344) 0.605 
 
0.555 (-0.594-1.516) 0.250 
 
 ≥0.8 448 (385-490) 
  
291 (262-353) 
  
0.262 (-0.753-1.272) 
  
Albumin (g/dl) 
        
 ≥3.8 446 (393-494) 0.591 
 
323 (289-363) <0.001 0.088 -0.380 (-1.125-0.957) <0.001 0.412  
 <3.8 455 (395-519) 
  
278 (245-306) 
  
0.702 (-0.175-1.617) 
  
ALT (IU/L) 
        
 <37 452 (397-505) 0.692 
 
295 (260-349) 0.967 
 
0.275 (-0.408-1.500) 0.600 
 
 ≥37 454 (389-498)     291 (262-326)     0.392 (-0.707-1.422)     
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Table 2C Oxidative stress markers in patients with HCV related HCC patients 
  
  
dROM, medium 
(range)(CARR/U) 
Univariate 
P-value  
Multivariate 
P-value  
OXY, medium 
(range)(CARR/U) 
Univariate 
P-value  
Multivariate 
P-value  
Oxidative Index, 
medium (range) 
Univariate 
P-value  
Multivariate 
P-value  
total 455 (393-534) 
  
279 (247-300) 
  
0.937 (-0.012-1.646) 
  
Age (years) 
         
 ≥67 463 (412-528) 0.571 0.626 270 (241-293) 0.155 0.390 1.241 (0.394-1.728) 0.268 
 
 <67 445 (373-550) 
  
280 (254-308) 
  
0.702 (-0.273-1.633) 
  
HCV-RNA (LogIU/ml) 
        
 ≥5.9 479 (415-538) 0.045 0.234 280 (247-296) 0.772 
 
0.982 (0.400-1.747) 0.158 
 
 <5.9 432 (363-499) 
  
276 (245-314) 
  
0.698 (-0.374-1.537) 
  
Ferritin 
(ng/ml)          
 ≥101 446 (385-507) 0.217 
 
279 (259-298) 0.373 
 
0.707 (-0.367-1.542) 0.050 
 
 <101 467 (397-541) 
  
273 (244-297) 
  
1.287 (0.540-1.806) 
  
Platelet(x104/mm3) 
        
 ≥9 459 (400-531) 0.563 
 
282 (250-306) 0.293 
 
1.133 (-0.031-1.625) 0.685 
 
 <9 454 (382-529) 
  
276 (245-292) 
  
0.931 (0.148-1.736) 
  
PT-INR 
         
 ≥1.02 454 (381-504) 0.371 
 
263 (245-282) 0.008 0.010 1.025 (0.110-1.744) 0.435 
 
 <1.02 459 (396-536) 
  
290 (265-316) 
  
0.959 (-0.121-1.565) 
  
Albumin 
(g/dl)          
 ≥3.4 479 (397-553) 0.163 
 
285 (259-312) 0.048 0.470 0.982 (-0.033-1.806) 0.903 
 
 <3.4 433 (379-500) 
  
265 (244-286) 
  
1.100 (0.028-1.631) 
  
AFP (ng/mL) 
         
 <18 437 (390-517) 0.425 
 
276 (245-311) 0.801 
 
0.982 (-0.039-1.471) 0.347 
 
 ≥18 479 (395-538) 
  
279 (250-296) 
  
0.937 (0.110-1.750) 
  
DCP 
(mAU/mL)          
 <76 449 (396-488) 0.705 
 
263 (239-295) 0.068 
 
1.141 (0.269-1.609) 0.576 
 
 ≥76 489 (370-546) 
  
281 (268-299) 
  
0.926 (-0.340-1.731) 
  
Stage 
         
 I+II 453 (396-527) 0.478 
 
276 (245-297) 0.503 
 
1.061 (0.033-1.559) 0.540  
 
 ＩＩＩ+IV 482 (378-614)     281 (254-305)     0.937 (-0.162-2.117)     
 
